The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis

Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis

June 16, 2020 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR BEYOND LIVE—Much, if not all, of rheumatology relies on clinical interpretation of historical, laboratory and imaging information to formulate a coherent diagnosis and treatment plan—even when such information is incomplete or has multiple possible interpretations. One of the best examples of this situation pertains to nonradiographic axial spondyloarthritis (nr-axSpA), a condition that is just now being recognized and described in a uniform manner.

You Might Also Like
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • From Chronic Low Back Pain to Axial Spondyloarthritis
Explore This Issue
July 2020
Also By This Author
  • DADA2: A New Disease for Rheumatologists to Understand

At the 2020 ACR State-of-the-Art Clinical Symposium, John Reveille, MD, professor and vice chair of medicine, University of Texas Health Science Center at Houston, discussed nr-axSpA in detail.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Progression of Criteria
In 2009, the Assessment of SpondyloArthritis International Society (ASAS) published classification criteria for nr-axSpA in which a patient who was younger than age 45 and had at least three months of chronic back pain could qualify for the diagnosis.

In one arm, patients who have HLA-B27 meet classification criteria if they also demonstrate two or more features of spondyloarthritis (i.e., inflammatory back pain, arthritis, heel enthesitis, uveitis, dactylitis, psoriasis, inflammatory bowel disease, good response to non-steroidal anti-inflammatory drugs [NSAIDs], family history of spondyloarthritis or elevated C-reactive protein [CRP]). In the other arm, patients with at least one clinical feature of spondyloarthritis plus inflammatory findings on magnetic resonance imaging (MRI) that are strongly suggestive of sacroiliitis—but lacking sacroiliac joint changes on radiographs that are not bilateral grade 2 or unilateral grade 3 or higher—would also meet criteria for nr-axSpA.1,2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

It’s important to note these criteria have been met with criticism. For example, the term nonradiographic axial spondyloarthritis can be unclear in that it includes patients with early radiographic sacroiliitis (e.g., grade 1 sacroiliitis bilaterally or grade 2 sacroiliitis unilaterally, as seen on radiography), and the ASAS criteria are unclear regarding whether radiographic changes can include the spine or only the sacroiliac joints.3

Nevertheless, Dr. Reveille made clear in his talk that the prevalence and burden of disease with respect to nr-axSpA should not be underestimated. In evaluating the 2009–10 National Health and Nutrition Examination Survey (NHANES), Weisman et al. noted the age-adjusted U.S. prevalence of inflammatory back pain by Calin criteria was 5.0%.4 

Deodhar et al. explained that in most cohorts and also in the NHANES study, the ratio of patients with nr-axSpA to those with ankylosing spondylitis (i.e., patients meeting radiographic imaging criteria) is 1:1.3 Yet in a study published last year describing diagnostic delay in identifying axial spondyloarthritis, the mean delay was 5.7 years, and factors associated with delayed diagnosis included female sex, those who are young at symptom onset, HLA-B27-negative status and the presence of psoriasis.5

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: ACR State-of-the-Art Clinical Symposium, criteria, non-radiographic axial spondyloarthritisIssue: July 2020

You Might Also Like:
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • From Chronic Low Back Pain to Axial Spondyloarthritis
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.